Novavax (NVAX +3.5%) gains after saying that Phase I clinical studies of it's investigational...

|By:, SA News Editor

Novavax (NVAX +3.5%) gains after saying that Phase I clinical studies of it's investigational avian influenza vaccine met their primary objectives of safety and immune response.